EN DE
Data-driven stock valuation

Amplia Therapeutics Limited (INNMF) fair value: what the stock is really worth

We calculate from audited financials what Amplia Therapeutics Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily, free.

  1. Compare price with fair valuebelow fair value = cheap, above = expensive
  2. Check the quality50 and up solid, 75 and up strong
  3. Watch it or check another stockalert when fair value or trend changes

Healthcare · US · Market cap $41.1M

At a glance

AT Amplia Therapeutics Limited logo Amplia Therapeutics Limited INNMF · US
Price$0.0900
Fair Value$0.0425
Upside−52.8%
Quality37/100

Below-average quality, and trading another 112% above our fair value of $0.0425.

As of Aug 20, 2026, the fair value of Amplia Therapeutics Limited is $0.0425 per share against a price of $0.0900, so the fair value sits 53% below the price. A model estimate from reported figures, not an analyst target.

!Mixed Growth (revenue 5y +156.3 %/yr)
!Loss-making · -160.9% net margin
!negative free cash flow
!Trails peers (1/10)
!Narrow moat 10/100
!Evidence only low, so the estimate is less certain
Evidence: Low Range $0.0255 to $0.0595

Fair value as of: Aug 20, 2026

From 3 valuation models · updated 22 days ago

Share price −10.0% over the past month.

Watch Amplia Therapeutics Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case ($0.0595). The favourable scenario is already priced in.
  • Weak quality (37/100) and above fair value at the same time, the margin of safety is missing on both counts.
  • The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
  • A fairly wide model range ($0.0255 to $0.0595) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

$0.2422 $0.0192 Fair Value $0.0425 Nov 2019 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 20, 2026.

How to read this chart

60‑month range $0.0192 – $0.2422 · fair‑value band $0.0255 – $0.0595 · the $0.0900 price screens above the $0.0425 fair value. Dashed = 300-day average. As of Aug 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Amplia Therapeutics Limited (INNMF) currently trades at $0.0900, while our model-based Fair Value estimate is $0.0425, implying the stock looks roughly 111.8% overvalued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: the Dividend Discount group reads highest at a median of $0.0500 per share, and 0 of the 3 models we run sit above the $0.0900 price. Bear case: the Asset-Based group reads lowest at $0.0300, and 3 of the 3 models stay below the price. Evidence for this calculation is low.

Trailing-twelve-month revenue stands at $4.8M. Revenue declined 9.1% year over year. It earns a return on equity of −25.5%. The balance sheet holds a net cash position of $10.8M. Fundamentals as of Aug 20, 2026

Scenario range: $0.0255 (bear) to $0.0595 (bull), the price of $0.0900 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target. The share trades about 67% below its 52-week high and 84% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −56% fair-value upside, at −53%, INNMF screens cheaper than that median.

Fair Value models

Each model values the company its own way; the fair value above is the evidence-weighted blend. Evidence (0 to 100) shows how complete a model's inputs are. How we calculate →

Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Gordon GGM best evidence $0.0300 $0.0500 $0.0600 67
DDM Multi-Stage $0.0300 $0.0500 $0.0500 65
NCAV (Graham) $0.0200 $0.0300 $0.0400 52
All 3 models by family
Dividend Discount
Gordon GGM best evidence $0.0300 $0.0500 $0.0600 67
DDM Multi-Stage $0.0300 $0.0500 $0.0500 65
Asset-Based
NCAV (Graham) $0.0200 $0.0300 $0.0400 52

Widest divergence: Dividend Discount ($0.0500) versus Asset-Based ($0.0300). Highest evidence: Gordon GGM (67).

Notify me when INNMF reaches fair value

Put INNMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/S ratio 8.57 TTM
EPS (TTM) $−0.0100
Dividend yield 5.1%
Net margin −161% TTM
Return on equity −25.5% TTM
Return on assets (EBIT) −25.4% avg 5y
More key figures
Profitability
Operating margin −186% TTM
Growth
Revenue (TTM) $4.8M TTM
Revenue growth (YoY) −9.1% 3y avg +24.0%
Balance sheet & cash flow
Free cash flow −$6.9M FY2025
Net cash $10.8M FY2025

Figures from reported company fundamentals · as of Aug 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 37/100

Of which business quality 39 · Market factors (momentum, volatility) 30

Profitability 6
Margins and returns on capital today
Quality Growth 32
Are margins and returns improving?
Cashflow 12
Earnings quality: real cash, not paper profit
Fin. Strength 99
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 28
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer.

Full company description

Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in phase 2b clinical trial for pancreatic cancer; and treatment of ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Amplia Therapeutics Limited reported revenue of A$3.8M in FY2025 versus A$1.5M in FY2021, a compound +25.3%/yr. Reported net income was −A$6.6M in FY2025.

Growth Quality 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
$3.8M
Latest YoY
−15.0%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+24.0%
Avg. revenue growth/yr (5Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+156.3%
Avg. revenue growth/yr (10Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+62.0%
EBIT margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,600.4% (2020) → −172.2% (2025)
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Revenue +25.3%/yr
FY21 A$1.5M
FY22 A$2.0M
FY23 A$1.2M
FY24 A$4.5M
FY25 A$3.8M
Net income
FY21 −A$2.3M
FY22 −A$3.6M
FY23 −A$6.2M
FY24 −A$4.5M
FY25 −A$6.6M

INNMF screens 112% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Amplia Therapeutics Limited · Fair Value
$0.0425 −112%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Amplia Therapeutics Limited Fair Value". https://www.fairvalue-calculator.com/stock/INNMF

Peer Group

Biotechnology · 635 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation
Quality Score 37 · Below median
Fair Value upside +135% · Top 25%
Profitability
Return on assets −16% · Below median
Net margin (TTM) −161% · Bottom 25%
Operating margin (TTM) −186% · Bottom 25%
Growth and dividend
Revenue growth −9% · Below median
Dividend yield (TTM) 5.1% · Top 25%

Valuation Multiples vs Biotechnology median · lower = cheaper

P/B 1.95× · Pricier than median
P/S (TTM) 8.57× · Pricier than median

Context: sector, industry, market

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE0 · sector 0
PAST0 · sector 0
HEALTH0 · sector 98
DIVIDEND100 · sector 27

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 20, 2026).

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $546.12 $278.78 −49%
Regeneron Pharmaceuticals, Inc REGN $827.72 $594.40 −28%
argenx SE ARGX €877.60 €292.84 −67%
BeOne Medicines AG 688235 ¥271.00 ¥47.36 −83%
Samsung Biologics Co 207940 1,452,000 KRW 1,055,793 KRW −27%
CSL Limited CSL A$174.50 A$141.68 −19%
Alnylam Pharmaceuticals, Inc ALNY $228.61 $51.70 −77%
Royalty Pharma plc RPRX $60.58 $24.22 −60%
Celltrion, Inc 068270 190,700 KRW 74,519 KRW −61%
BioNTech SE BNTX $103.76 $45.70 −56%

Compare Amplia Therapeutics Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Frequently asked questions

Is Amplia Therapeutics Limited (INNMF) overvalued or undervalued?
As of Aug 20, 2026, our model estimates a fair value of $0.0425 versus a price of $0.0900, about −53% upside (overvalued).
What is the fair value of INNMF?
Our model-based fair value for Amplia Therapeutics Limited is $0.0425 (as of Aug 20, 2026), built from audited fundamentals. The current price: $0.0900.
What is the quality score of INNMF?
Amplia Therapeutics Limited has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Amplia Therapeutics Limited (INNMF)?
Our model-based price target is the fair value of $0.0425 (as of Aug 20, 2026) from 3 valuation models. Cautious scenario $0.0255, optimistic scenario $0.0595. It is a calculation from audited fundamentals, not an analyst target.
What is the Amplia Therapeutics Limited stock forecast for 2026?
Our models put fair value at $0.0425, about −53% upside versus a price of $0.0900 (overvalued). Cautious scenario $0.0255, optimistic scenario $0.0595. The calculation is refreshed regularly with new filings.
What is the revenue of Amplia Therapeutics Limited (INNMF)?
Amplia Therapeutics Limited reported trailing-twelve-month revenue of about $4.8M (latest available figure, as of Aug 20, 2026).
What is the net profit margin of INNMF?
The net profit margin of Amplia Therapeutics Limited is about −160.9%, meaning it is currently running at a net loss. Based on the latest reported figures.
Does Amplia Therapeutics Limited pay a dividend?
Amplia Therapeutics Limited currently shows a dividend yield of about 5.11% relative to its recent price (as of Aug 20, 2026).
What is the intrinsic value of Amplia Therapeutics Limited (INNMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Amplia Therapeutics Limited it is $0.0425 per share (as of Aug 20, 2026), against a price of $0.0900. It is the blended result of 3 valuation models (cash flow, earnings, asset, dividend).
Is Amplia Therapeutics Limited stock overvalued or undervalued in 2026?
As of Aug 20, 2026, INNMF trades above its calculated fair value: price $0.0900, fair value $0.0425, a gap of about −53% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of INNMF?
No. The price is what the market pays today ($0.0900); the fair value is what the company's own numbers justify ($0.0425). For Amplia Therapeutics Limited the two are $0.0475 per share apart. That gap is exactly why we show both numbers side by side.
How much is Amplia Therapeutics Limited worth?
The market values Amplia Therapeutics Limited at about $41.1M (market capitalisation, as of Aug 20, 2026). Per share that is $0.0900; our models calculate a fair value of $0.0425 per share.
What do the bullish and bearish scenarios say about INNMF?
Our models span a range for Amplia Therapeutics Limited: cautious scenario $0.0255, base $0.0425, optimistic $0.0595 per share (as of Aug 20, 2026, price $0.0900). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Amplia Therapeutics Limited (INNMF)?
Balance-sheet figures for Amplia Therapeutics Limited (as of Aug 20, 2026): return on equity −25.5%. They feed the Quality Score of 37/100, which measures business quality independently of the share price.
How far is INNMF from its 52-week high?
Amplia Therapeutics Limited trades at $0.0900, about 67% below its 52-week high of $0.2720 and 84% above the low of $0.0490 (as of Aug 20, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0425 is for.
Which stocks are comparable to Amplia Therapeutics Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, BeOne Medicines AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Amplia Therapeutics Limited stock attractive at the current price?
The data as of Aug 20, 2026: price $0.0900, calculated fair value $0.0425 (−53%), Quality Score 37/100, from 3 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of INNMF calculated?
We run Amplia Therapeutics Limited through 3 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0425, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 32.6 % above its aggregate fair value. Amplia Therapeutics Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on <a href="/is-it-worth-investing-now/">is it worth investing now</a>.
Free · no account needed

Watch Amplia Therapeutics Limited in the live analysis

One click puts Amplia Therapeutics Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.